EMA Authorised: Olanzapine Teva (olanzapine) — Teva B.V.

View source ↗

Summary

The EMA authorised Teva B.V. to market Olanzapine for schizophrenia and bipolar disorder in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Olanzapine Teva (olanzapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Teva B.V.. Decision date: 12/05/2025